Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide + Insulin Glargine versus Insulin Lispro + Insulin Glargine in Type 2 Diabetes Mellitus (Switch Study)
2014-001821-34Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of albiglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GSK. Primary endpoint: Primary glycemic effectiveness endpoint. Started Oct 2014; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-001821-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001821-34.